Recherche
-
Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study
(European Journal of Epidemiology. pp. 1-11, 2022-09-21)Article de revue -
Use of cardiovascular and antidiabetic drugs during COVID19 epidemic in France
(Fundamental & Clinical Pharmacology. vol. 36, n° S1, pp. 94-95, 2022-06)Article de revue -
Bidisciplinary dermatology-pharmacovigilance consultations: Results of a two-year study
(Annales de Dermatologie et de Vénéréologie, 2022-12-07)Article de revue -
Risk of first ischemic stroke and use of antidopaminergic antiemetics: A nationwide case-time-control study
(Fundamental and Clinical Pharmacology. vol. 36, pp. 22-23, 2022-06)Article de revue -
Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ?
(Therapies. vol. 78, n° 1, pp. 115-129, 2022-11-25)Article de revue -
High-Dimensional Propensity Score-Adjusted Case-Crossover for Discovering Adverse Drug Reactions from Computerized Administrative Healthcare Databases
(Drug Safety, 2022-02-18)Article de revue -
Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study
(The Lancet Regional Health - Europe. vol. 17, 2022-06)Article de revueLibre accès -
Myocardial infarction associated with erenumab: a case report.
(PHARMACOTHERAPY, 2022-05-27)Article de revueLibre accès -
Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data
(Drug Safety. vol. 45, n° 5, pp. 535-548, 2022-05)Article de revueLibre accès -
Emergency room admissions induced by drug-drug interactions in the elderly: a cross-sectional study
(Clinical and Translational Science, 2022-03-04)Article de revueLibre accès